Related Experiment Videos

HMB-45 staining in benign and malignant melanocytic lesions. A reflection of cellular activation

H G Skelton1, K J Smith, T L Barrett

  • 1Department of Dermatopathology, Armed Forces Institute of Pathology, Washington, DC 20306-6000.

Insights

The HMB-45 antibody, a melanoma marker, also stains benign melanocytic lesions. Its reactivity correlates with melanosome production, indicating melanocytic origin and proliferation in various nevi and melanomas.

Area of Science:

  • Dermatopathology
  • Immunohistochemistry
  • Oncology

Background:

  • The HMB-45 antibody is commonly used as an immunohistochemical marker for melanoma.
  • However, positive HMB-45 staining has been observed in some benign melanocytic lesions, questioning its specificity.

Purpose of the Study:

  • To evaluate the expression of HMB-45 in a wide spectrum of benign and malignant melanocytic lesions.
  • To determine the correlation of HMB-45 staining with melanosome production and melanocytic proliferation.

Main Methods:

  • Immunoperoxidase staining for S-100 protein and HMB-45 was performed on 225 biopsy specimens.
  • Lesions included various types of nevi (common acquired, Spitz, cellular blue, deep penetrating, congenital, genital) and melanomas (malignant, desmoplastic malignant).

Main Results:

  • HMB-45 showed positive staining in the dermal component of most benign and malignant melanocytic lesions studied.
  • Common acquired nevi and desmoplastic malignant melanomas were uniformly negative for HMB-45 in the dermal component.
  • HMB-45 reactivity was found to correlate with melanosome production, suggesting melanocytic origin.

Conclusions:

  • HMB-45 is a useful marker for melanocytic differentiation, correlating with melanosome production.
  • Its expression is influenced by factors stimulating melanocytic proliferation, and it is present in various melanocytic lesions beyond just melanoma.

Related Concept Videos